HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of vascular response after sirolimus-eluting stent implantation between patients with unstable and stable angina pectoris: a serial optical coherence tomography study.

AbstractOBJECTIVES:
The aim of the present study was to compare lesion morphologies after sirolimus-eluting stent (SES) implantation between patients with unstable angina pectoris (UAP) and stable angina pectoris (SAP) with the use of optical coherence tomography (OCT).
BACKGROUND:
The lesion morphologies before and after coronary stenting have been proposed as important predictors of clinical outcome. The high resolution of OCT provides detailed information of coronary vessel wall.
METHODS:
We enrolled 55 patients (UAP: n = 24, SAP: n = 31), and examined lesion morphologies by using OCT at pre- and post-SES implantation and 9 months' follow-up.
RESULTS:
The incidence of plaque rupture (42% vs. 3%, p < 0.001), intracoronary thrombus (67% vs. 3%, p < or = 0.001) and thin-capped fibroatheroma (cap thickness <65 microm; 46% vs. 3%, p < 0.001) at pre-intervention was significantly greater in UAP than that in SAP. Although stent profiles and procedural characteristics were not different between the 2 groups, inadequate stent apposition (67% vs. 32%, p = 0.038) and tissue protrusion (79% vs. 42%, p = 0.005) after percutaneous coronary intervention were observed more frequently in patients with UAP. Plaque rupture was significantly increased after percutaneous coronary intervention in patients with UAP (42% to 75%, p = 0.018), and the persistence of core cavity after plaque rupture (28% vs. 4%, p = 0.031) at 9 months' follow-up was observed more frequently in UAP patients compared with SAP patients. At 9 months' follow-up, the incidence of inadequately apposed stent (33% vs. 4%, p = 0.012) and partially uncovered stent by neointima (72% vs. 37%, p = 0.019) was significantly greater in UAP patients than that in SAP patients. All patients took aspirin and ticlopidine during follow-up period, and no patients had stent thrombosis or adverse coronary events.
CONCLUSIONS:
Serial OCT examinations demonstrated markedly different vascular response up to 9 months after SES implantation between UAP and SAP patients. Although the inadequate lesion morphologies after stenting were observed more frequently in UAP patients, these findings were not associated with adverse outcomes in patients with antiplatelet therapy.
AuthorsTakashi Kubo, Toshio Imanishi, Hironori Kitabata, Akio Kuroi, Satoshi Ueno, Takashi Yamano, Takashi Tanimoto, Yoshiki Matsuo, Takashi Masho, Shigeho Takarada, Atsushi Tanaka, Nobuo Nakamura, Masato Mizukoshi, Yoshiaki Tomobuchi, Takashi Akasaka
JournalJACC. Cardiovascular imaging (JACC Cardiovasc Imaging) Vol. 1 Issue 4 Pg. 475-84 (Jul 2008) ISSN: 1876-7591 [Electronic] United States
PMID19356470 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Cardiovascular Agents
  • Platelet Aggregation Inhibitors
  • Sirolimus
Topics
  • Aged
  • Angina Pectoris (etiology, pathology, therapy)
  • Angina, Unstable (etiology, pathology, therapy)
  • Angioplasty, Balloon, Coronary (adverse effects, instrumentation)
  • Cardiovascular Agents (administration & dosage)
  • Coronary Angiography
  • Coronary Artery Disease (complications, pathology, therapy)
  • Coronary Vessels (pathology)
  • Drug-Eluting Stents
  • Female
  • Humans
  • Male
  • Middle Aged
  • Observer Variation
  • Platelet Aggregation Inhibitors (therapeutic use)
  • Predictive Value of Tests
  • Prospective Studies
  • Rupture
  • Sirolimus (administration & dosage)
  • Thrombosis (etiology, pathology)
  • Time Factors
  • Tomography, Optical Coherence
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: